Test Price
2,800 AEDโ Home Collection Available
EIF4E Gene Mutation Analysis (Autism Susceptibility Type 19) by NGS in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Advanced Genetic Screening for Autism Susceptibility Type 19
This targeted Next-Generation Sequencing (NGS) assay detects pathogenic variants in the EIF4E gene, providing precise molecular confirmation of Autism Susceptibility Type 19. The test delivers definitive results for affected families while ensuring strict clinical governance across the UAE.
- 99.9% Diagnostic Sensitivity โ Validated via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139), guaranteeing reliable variant calling across all coding exons.
- Premium Logistics โ VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across all emirates. Direct billing verification via WhatsApp +971 54 548 8731; most major UAE insurers accepted.
- Clinical Guidance โ Complimentary telephonic post-test consultation with a DHA-licensed genetic counselor to interpret results within the broader autism spectrum context.
Test Overview & Methodology
The EIF4E Gene NGS test screens for single-nucleotide variants and small insertions/deletions linked to Autism Susceptibility Type 19. By focusing exclusively on the EIF4E locus, this targeted approach achieves superior diagnostic yield compared to broader genomic panels, enabling faster, cost-effective insights for families pursuing a molecular diagnosis.
| Parameter | EIF4E Targeted NGS | Whole Exome Sequencing (Alternative) |
|---|---|---|
| Analytical Precision | 99.9% sensitivity for EIF4E coding exons; deep 300x read depth | Broader coverage but lower average depth (100x); may miss deep intronic variants |
| Methodology | Next-Generation Sequencing (NGS) with targeted capture enrichment | Exome-wide NGS requiring extensive bioinformatics filtering |
| Turnaround Time | 3โ4 weeks (focused single-gene analysis) | 4โ6 weeks (complex multi-gene data interpretation) |
Physician Insight & Safety Protocols
"The EIF4E gene is a well-established contributor to autism susceptibility through its role in mRNA translation regulation. A targeted NGS assay provides high-confidence variant detection, but the result must always be contextualized within a comprehensive developmental assessment. A positive finding confirms a genetic predisposition; a negative result does not exclude other heritable or environmental factors. Responsible interpretation requires integration with family history and clinical evaluation." โ Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA License No. 9294403)
Medical Advisory
Prescription & Therapy Caution
Genetic test results are intended for diagnostic and risk assessment purposes only. Do not alter, initiate, or discontinue any prescribed medications, behavioral therapies, or developmental interventions without direct consultation with your managing physician. Self-adjustment of treatment based on genetic data may lead to adverse clinical outcomes.
Exclusion Criteria & Safety Red Flags
- Active febrile illness or systemic infection at time of sample collection โ defer testing until fully resolved.
- Known coagulopathy or platelet count below 50,000/ยตL for venipuncture; buccal swab or FTA card collection is a safe alternative.
- Emergency Advisory: If test results trigger acute psychological distress, agitation, or self-harm ideation, seek immediate evaluation at the nearest emergency department.
Patient FAQ & Clinical Guidance
1. How accurate is the EIF4E gene test for diagnosing autism?
The EIF4E NGS test delivers 99.9% analytical sensitivity for single nucleotide variants and small indels within the gene's coding region, providing reliable molecular confirmation of Autism Susceptibility Type 19. This focused approach minimizes false negatives compared to broader genomic screens.
2. Can this test be performed on a child under 5 years?
Yes, the test is safe for neonates and children. A single drop of blood collected on an FTA card or a painless buccal swab eliminates venipuncture stress. Sample collection follows Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all minor consent protocols.
3. What support is provided after results are delivered?
Results are reported within 3 to 4 weeks. A DHA-licensed genetic counselor provides a complimentary telephonic consultation to explain findings, discuss implications for family planning, and recommend next clinical steps. This service ensures you understand the result in the full context of your family's health.
UAE Regulatory & Data Privacy Adherence
Data Protection Framework: All genetic data is processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE maintains strict data encryption, access controls, and audit trails to safeguard your genomic information.
DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
Clinical & Logistical Metadata
| Test Name | EIF4E Gene Mutation Analysis (Autism Susceptibility Type 19) by NGS |
| Price (AED) | 2,800 |
| Turnaround Time | 3โ4 weeks |
| Sample Type / Matrix | Peripheral whole blood (FTA card compatible) or buccal swab |
| Methodology Used | Next-Generation Sequencing (NGS) with targeted capture enrichment |
| ICD-10-CM Code | F84.0 |
| LOINC Code | 21647-3 |
| DHA License & Lab Address | DHA Facility License No. 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians